Skip to content
10-Q

Quarterly Report

Raphael Pharmaceutical Inc. RAPH

0001213900-23-086894

← back to feed
Filed
Nov 14, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Nov 14, 2023 18.1M sh
Cash And Equivalents Q3 2023 · Sep 30, 2023 $299K
Cash And Equivalents Q3 2023 · Dec 31, 2022 $288K
Current Liabilities Q3 2023 · Sep 30, 2023 $478K
Current Liabilities Q3 2023 · Dec 31, 2022 $227K
Current Assets Q3 2023 · Sep 30, 2023 $402K
Current Assets Q3 2023 · Dec 31, 2022 $331K
Total Assets Q3 2023 · Sep 30, 2023 $403K
Total Assets Q3 2023 · Dec 31, 2022 $333K
Shares Diluted Q3 2023 · Sep 30, 2022 15.06M sh
Shares Diluted Q3 2023 · Sep 30, 2022 13.92M sh
Operating Cash Flow Q3 2023 · Sep 30, 2022 −$482K
Stockholders Equity Q3 2023 · Sep 30, 2022 −$62K
Stockholders Equity Q3 2023 · Jun 30, 2022 $118K
Stockholders Equity Q3 2023 · Dec 31, 2021 $128K
Eps Diluted Q3 2023 · Sep 30, 2022 $0.10
Eps Diluted Q3 2023 · Sep 30, 2022 $0.16
Eps Basic Q3 2023 · Sep 30, 2022 $0.10
Eps Basic Q3 2023 · Sep 30, 2022 $0.16
Sga Expense Q3 2023 · Sep 30, 2022 $1.09M
Sga Expense Q3 2023 · Sep 30, 2022 $1.71M
Rd Expense Q3 2023 · Sep 30, 2022 $332K
Rd Expense Q3 2023 · Sep 30, 2022 $502K
Net Income Q3 2023 · Sep 30, 2022 −$1.44M
Net Income Q3 2023 · Sep 30, 2022 −$2.26M
Net Income Q3 2023 · Jun 30, 2022 −$812K
Operating Income Q3 2023 · Sep 30, 2022 −$1.43M
Operating Income Q3 2023 · Sep 30, 2022 −$2.21M